Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53 - 00144, Rome, Italy.
Phase I Clinical Studies & Precision Medicine, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53 - 00144, Rome, Italy.
Future Oncol. 2021 Sep;17(26):3445-3456. doi: 10.2217/fon-2021-0300. Epub 2021 May 28.
Eribulin shows some activity in controlling brain metastasis in breast cancer. This observational, multicenter study evaluated brain disease control rates, survival and safety in patients with brain metastatic breast cancer treated with eribulin in clinical practice. A total of 34 patients were enrolled (mean age 49 years, 91% with visceral metastases) and 29 were evaluable for brain disease. Fourteen achieved disease control and showed a longer time without progression: 10 months (95% CI: 2.3-17.7) versus 4 months (95% CI: 3.3-4.7) in the control group (p = 0.029). Patients with clinical benefits at 6 months had longer survival. Leukopenia and neutropenia were the most frequent grade 3-4 toxicities. Eribulin confirms its effectiveness in patients with brain metastatic breast cancer. Further studies on larger cohorts are needed to confirm the results.
依立布林在控制乳腺癌脑转移方面具有一定的活性。本观察性、多中心研究评估了在临床实践中使用依立布林治疗脑转移乳腺癌患者的脑疾病控制率、生存和安全性。共纳入 34 例患者（平均年龄 49 岁，91%有内脏转移），29 例患者可评估脑疾病。14 例患者达到疾病控制，且无进展时间更长：10 个月（95%CI：2.3-17.7）与对照组的 4 个月（95%CI：3.3-4.7）相比（p = 0.029）。6 个月时具有临床获益的患者生存时间更长。白细胞减少和中性粒细胞减少是最常见的 3-4 级毒性。依立布林在脑转移乳腺癌患者中证实了其有效性。需要进一步研究更大的队列来确认这些结果。
